Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

• DOI: 10.1200/jco.23.01909
• Publication Date: 2024-04-23T20:02:21Z
• Authors: Aditya Bardia; Ian E. Krop; Takahiro Kogawa; Dejan Juric; Anthony W. Tolcher; Erika P. Hamilton; Toru Mukohara; Aaron Lisberg; Toshio Shimizu; Alexander I. Spira; Junji Tsurutani; Senthil Damodaran; Kyriakos P. Papad...; Jonathan Greenberg; Fumiaki Kobayashi; Hong Zebger-Gong; Rie Wong; Yui Kawasaki; Tadakatsu Nakamura; Funda Meric-Bernstam
• Keywords: Tolerability; Triple-negative breast cancer

Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to potent, exatecan-derived topoisomerase I inhibitor payload via plasma-stable, selectively cleavable linker.